Abstract
11C-SCH442416 was reported in preclinical studies with rodents and primates to be the first nonxanthine radioligand suitable for the in vivo imaging of adenosine A2A receptors with positron emission tomography (PET). The aim of the present work was to investigate the suitability of 11C-SCH442416 for the in vivo quantification of A2A receptors in human brain. Methods: Five male healthy subjects were scanned with 364 MBq bolus injections of 11C-SCH442416. 90 minutes of dynamic PET emission data were acquired, and arterial blood samples were taken throughout the scan to generate an arterial plasma input function. Using the individual MR images, regions-of-interest (ROIs) were defined for cerebellum, caudate, putamen and thalamus. Spectral analysis was used to determine the frequency components of the 11C-SCH442416 tissue response for regional and voxel time-activity curves (TACs). Results: 11C-SCH442416 was rapidly metabolised in blood, the fraction of unmetabolised parent tracer in plasma being 41% at 15 minutes and 15% at 95 minutes, lower than that reported in rats and macaca nemestrina. No lipophilic radiolabelled metabolites were found in human plasma. Rapid uptake of 11C-SCH442416 was observed in all brain regions, reaching a maximum at about 3 minutes. When spectral analysis was applied to regional brain time activity curves (TACs), relatively rapid reversible region dependent and slower irreversible, region independent but subject specific components were identified. These components were further separated into irreversible nonspecific binding, reversible nonspecific binding, reversible specific binding and a blood component. Binding potentials of the nondisplaceable binding BPND were calculated using cerebellar volume of distribution as an estimate of the reversible nondisplaceable binding across the entire brain. Mean binding potentials BPND were: 2.5 (putamen), 1.6 (caudate) and 0.5 (thalamus). Conclusion: Our study demonstrates that A2A receptor binding can be quantified in striatal regions of the human brain with 11C-SCH442416 PET. Despite the complex tracer kinetics and its low specific binding, reliable binding potentials could be estimated with spectral analysis.
Highlights
When spectral analysis was applied to regional brain time activity curves (TACs), relatively rapid reversible region dependent and slower irreversible, region independent but subject specific components were identified
Our study demonstrates that A2A receptor binding can be quantified in striatal regions of the human brain with 11C-SCH442416 positron emission tomography (PET)
Adenosine is an endogenous modulator of neurotransmission that acts via an interaction with Gprotein-coupled receptors in the central nervous system (CNS)
Summary
Adenosine is an endogenous modulator of neurotransmission that acts via an interaction with Gprotein-coupled receptors in the central nervous system (CNS). Adenosine A2A receptors are abundant in the caudateputamen, nucleus accumbens, and olfactory tubercle [1,2]. The roles of adenosine are not fully understood, it has been suggested that adenosine A2A receptor activation may be involved in mediating a number of physiological functions in the CNS, including locomotion via regulation of the indirect striatal pathway to the internal pallidum and mood via its action on the ventral striatum. Potential therapeutic areas for agents acting at central A2A receptors include schizophrenia, attention deficit hyperactivity disorder, anxiety disorders, depression, Huntington’s disease, Gilles de la Tourette syndrome and Parkinson’s disease.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
